Diversified Trust Co Sells 5,090 Shares of Ascendis Pharma A/S $ASND

Diversified Trust Co trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 12.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,161 shares of the biotechnology company’s stock after selling 5,090 shares during the quarter. Diversified Trust Co owned 0.06% of Ascendis Pharma A/S worth $8,500,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S in the second quarter worth approximately $166,367,000. Wellington Management Group LLP boosted its holdings in Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after acquiring an additional 880,836 shares during the period. Vestal Point Capital LP boosted its holdings in Ascendis Pharma A/S by 200.0% during the 3rd quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after acquiring an additional 400,000 shares during the period. Spyglass Capital Management LLC purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at $77,267,000. Finally, Principal Financial Group Inc. grew its position in Ascendis Pharma A/S by 29.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after acquiring an additional 232,730 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND opened at $230.83 on Friday. The firm has a market capitalization of $14.40 billion, a PE ratio of 26.62 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The business’s 50-day moving average is $232.32 and its two-hundred day moving average is $224.27. Ascendis Pharma A/S has a 1 year low of $160.86 and a 1 year high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. Research analysts anticipate that Ascendis Pharma A/S will post 4.55 earnings per share for the current fiscal year.

Insider Activity at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jean Jacques Bienaime acquired 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average cost of $237.80 per share, with a total value of $95,120.00. Following the transaction, the director directly owned 400 shares in the company, valued at approximately $95,120. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ASND. Evercore reissued an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday. Wolfe Research reissued an “outperform” rating and set a $260.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Finally, Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.